A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s 3A4, 2C8, 2C9, 2C19, and 2D6

Trial Profile

A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s 3A4, 2C8, 2C9, 2C19, and 2D6

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2018

At a glance

  • Drugs Relacorilant (Primary) ; Metoprolol; Midazolam; Omeprazole; Pioglitazone; Tolbutamide
  • Indications Alcoholism; Cushing syndrome; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Corcept Therapeutics
  • Most Recent Events

    • 16 May 2018 Status changed from recruiting to completed.
    • 13 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 09 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top